|
|
Fluconazole
|
|
MethylGene Reports Clinical Data for MGCD265 at the 2011 American Society of ... - Marketwire (press release) Marketwire (press release)--The Company's lead product candidates include: MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers and MGCD290, a fungal Hos2 inhibitor, for use in combination w - Date : Fri, 03 Jun 2011 12:02:01 GMT+00:00 |
MethylGene Closing Private Placement - PR-USA.net (press release) PR-USA.net (press release)--The Company's lead product candidates include: MGCD265, an oral multi-targeted kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers and MGCD290, a fungal Hos2 inhibitor, for use in combination with - Date : Sun, 03 Apr 2011 06:20:11 GMT+00:00 |
MethylGene Reports Fourth Quarter and Full Year 2010 Financial Results - SYS-CON Media (press release) SYS-CON Media (press release)--The Company's lead product candidates include: MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers and MGCD290, a fungal Hos2 inhibitor, for use in combinatio - Date : Wed, 30 Mar 2011 11:36:36 GMT+00:00 |
MethylGene Reports Fourth Quarter and Full Year 2010 Financial Results - PR-USA.net (press release) PR-USA.net (press release)--The Company's lead product candidates include: MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers and MGCD290, a fungal Hos2 inhibitor, for use in combination w - Date : Thu, 31 Mar 2011 12:35:37 GMT+00:00 |
Overgrowth of yeast causes host of issues - Wilkes Barre Times-Leader Wilkes Barre Times-Leader--To kill off an existing candida overgrowth, he uses prescription medications, such as -fluconazole-, an antifungal, and natural remedies such as castor bean oil extract and caprylic acid. Crooker used some of those remedies. ... - Date : Tue, 29 Mar 2011 05:25:29 GMT+00:00 |
MethylGene to Present MGCD265 Data at the American Association for Cancer ... - Marketwire (press release) Marketwire (press release)--The Company's lead product candidates include: MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers and MGCD290, a fungal Hos2 inhibitor, for use in combination w - Date : Tue, 29 Mar 2011 11:32:56 GMT+00:00 |
MethylGene Announces $34.5 Million Financing to Develop Oncology & Antifungal ... - BioMedReports (subscription) BioMedReports (subscription)--The proceeds of the financing will also be used to fund Phase 2 studies with MGCD290+-fluconazole- in vulvovaginal candidiasis (VVC) which is caused by the Candida fungus. Antifungal drugs, particularly the family of drugs ca - Date : Thu, 24 Mar 2011 22:07:52 GMT+00:00 |
Prevalence of invasive fungal disease in hematological patients at a tertiary ... - 7thSpace Interactive (press release) 7thSpace Interactive (press release)---Fluconazole- prophylaxis had been provided for 28 out of the 39 (71.8%) cases, while 4 (10.3%) were on itraconazole prophylaxis. The in-hospital mortality was 28.2% (11 of 39 cases), of which 5 (12.8%) deaths were at - Date : Mon, 28 Feb 2011 16:05:37 GMT+00:00 |
ATS issues statement on the treatment of pulmonary fungal infections - EurekAlert (press release) EurekAlert (press release)---...- itraconazole and -fluconazole-, the guidelines include recommendations for use of newer agents, including extended-spectrum triazoles and echinocandins, ... - Date : Mon, 03 Jan 2011 19:27:08 GMT+00:00 |
MethylGene Presents Favorable Clinical Data for Mocetinostat at the 52nd ... - PR-CANADA.net (press release) PR-CANADA.net (press release)---...- MGCD290, a fungal Hos2 inhibitor for use in combination with -fluconazole- for fungal infections which has completed Phase 1 clinical studies; ... - Date : Wed, 08 Dec 2010 09:21:04 GMT+00:00 |
Wall/ membrane | ||
---|---|---|
Wall/ membrane | ||
---|---|---|
Wall/ membrane | ||
subgroup |
Wall/ membrane | ||
---|---|---|
Wall/ membrane | ||
subgroup | ||
Wall/ membrane | ||
subgroup
|groupstyle=background:PowderBlue;
|Ergosterol inhibitors | | ||
Polyene antimycotics (ergosterol binding) | ||
topical: (Natamycin, Nystatin#) systemic: (Amphotericin B#) | ||
Allylamines (squalene monooxygenase inhibitors) | ||
topical: (Amorolfine, Butenafine, Naftifine, Terbinafine) systemic: (Terbinafine) |